AI predicts liver cancer return, guides personalized drug cocktail
NCT ID NCT07282184
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with early-stage liver cancer who are scheduled for surgery. Researchers are testing whether an artificial intelligence (AI) tool can predict each patient's risk of the cancer returning. Patients identified as high-risk will receive a combination of chemotherapy, targeted therapy, and immunotherapy before and after surgery. The goal is to see if this personalized plan improves the chance of staying cancer-free for two years compared to surgery alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Combination of chemotherapy (HAIC with mFOLFOX6), oral Lenvatinib, and a PD-1 inhibitor
- What this could lead to
- If successful, this approach could offer a personalized treatment plan that significantly lowers the chance of liver cancer returning after surgery.
- What could go wrong
- This is an early-phase trial with only 144 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and the AI tool's predictions may not always be accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPOTACELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 438700, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.